MD  >> Vol. 7 No. 3 (September 2017)

    Expression of TGF-β1 and ALDH1 and Their Clinical Significance in Patients with Intrahepatic Cholangiocarcinoma

  • 全文下载: PDF(886KB) HTML   XML   PP.65-72   DOI: 10.12677/MD.2017.73011  
  • 下载量: 156  浏览量: 292  


双泽宇,李升平:华南肿瘤学国家重点实验室,中山大学肿瘤防治中心,广东 广州

肝内胆管细胞癌转化生长因子β1乙醛脱氢酶1预后Intrahepatic Cholangiocarcinoma TGF-β1 ALDH1 Prognosis


背景:乙醛脱氢酶1 (ALDH1)可作为多种肿瘤干细胞的标志,而对其来源报道较少。体外研究表明转化生长因子β1( transforming growth factorβ1, TGF-β1)能诱导肿瘤干细胞的产生,而胆管细胞癌组织中TGF-β1表达与ALDH1的关系尚未阐明。方法:采用定量PCR检测7例正常胆管、18例胆管细胞癌新鲜组织中TGF-β1和ALDH1 mRNA的表达,免疫组织化学染色的方法检测58例肝内胆管细胞癌石蜡组织中TGF-β1和ALDH1蛋白的表达。结果:胆管细胞癌组织中TGF-β1的mRNA水平明显高于正常胆管(P = 0.046),ALDH1的mRNA水平无统计学差异。肝内胆管细胞癌组织中TGF-β1低表达组28例,高表达组30例,高表达阳性率为51.72%,ALDH1低表达组23例,高表达组35例,高表达阳性率为60.34%,TGF-β1与ALDH1的表达呈正相关(r = 0.583, P < 0.001)。肝内胆管癌组织中TGF-β1及ALDH1表达在肿瘤低分化组高于高分化组(P值分别为0.003、0.011),ALDH1表达在术前血浆CA199浓度高水平组高于低水平组(P = 0.041)。肝内胆管细胞癌组织中TGF-β1及ALDH1高水平组患者的总生存率低于低水平组(P值分别为0.012、0.033)。多因素Cox回归模型分析显示TGF-β1表达量是影响肝内胆管细胞癌患者预后的独立危险因素(P = 0.014)。结论:肝内胆管细胞癌组织中TGF-β1表达与ALDH1表达有关;肝内胆管细胞癌组织中TGF-β1表达量可作为预测患者术后预后的指标。

Background: Aldehyde dehydrogenase 1 (ALDH1) has been proved to be the marker of cancer stem cells (CSCs) in different types of tumors. However, the research of its source is rare. Recent studies showed that transforming growth factor β1 (TGF-β1) could induce the generation of CSCs. However, the correlation of TGF-β1 and ALDH1 expression in patients with intrahepatic cholangiocarcinoma (ICC) is unclear. Method: Expression of TGF-β1 and ALDH1 were detected in seven normal bile duct and eighteen cholangiocarcinoma tissues by quantitative PCR. Expression of TGF-β1 and ALDH1 were detected in fifty eight ICC tissues by using immunohistochemistry (IHC) technique. Results: Quantitative PCR showed that the expression of TGF-β1 in cholangiocarcinoma patients was higher than normal bile duct (P = 0.046). Immunohistochemical staining showed that the expression of TGF-β1 was correlated with the expression of ALDH1 in ICC patients (P < 0.001). Both of TGF-β1 and ALDH1 expression were correlated with tumor differentiation (P = 0.003 or P = 0.011) and ALDH1 expression was correlated with the level of CA199 (P = 0.041). Both of TGF-β1 and ALDH1 expression were prognostic factors in ICC patients (P = 0.012 or P = 0.033). Cox multivariate model showed that TGF-β1 expression was independent prognostic factors in ICC patients (P = 0.014). Conclusion: The expression of TGF-β1 is related to the expression of ALDH1 in ICC patients. And the expression of TGF-β1 can be used as the independent predictor for the prognosis of patients with ICC.

双泽宇, 李升平. 转化生长因子β1与乙醛脱氢酶1在肝内胆管细胞癌的表达及其临床意义[J]. 医学诊断, 2017, 7(3): 65-72.


[1] Shaib, Y. and El-Serag, H.B. (2004) The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease, 24, 115- 125.
[2] Blechacz, B.R. and Gores, G.J. (2008) Cholangiocarcinoma. Clinical Liver Disease, 12, 131-150.
[3] Tomita, H., Tanaka, K., Tanaka, T. and Hara, A. (2016) Aldehyde Dehydrogenase 1A1 in Stem Cells and Cancer. Oncotarget, 7, 11018-11032.
[4] Bellomo, C., Caja, L. and Moustakas, A. (2016) Transforming Growth Factor β as Regulator of Cancer Stemness and Metastasis. British Journal of Cancer, 115, 761-769.
[5] Shi, Y. and Massagué, J. (2003) Mechanisms of TGF-Beta Signaling from Cellmembrane to the Nucleus. Cell, 113, 685-700.
[6] Paik, S.Y., Park, Y.N., Kim, H. and Park, C. (2003) Expression of Transforming Growth Factor-Beta1 and Transforming Growth Factor-Beta Receptors in Hepatocellular Carcinoma and Dysplastic Nodules. Modern Pathology, 16, 86- 96.
[7] Bedossa, P., Peltier, E., Terris, B., Franco, D. and Poynard, T. (1995) Transforming Growth Factor-Beta 1 (TGF-Beta 1) and TGF-Beta 1 Receptors in Normal, Cirrhotic, and Neoplastic Human Livers. Hepatology, 21, 760-766.
[8] Tirado-Rodriguez, B., Ortega, E., Segura-Medina, P. and Huerta-Yepez, S. (2014) TGF-β1: An Im-portant Mediator of Allergic Disease and a Molecule with Dual Activity in Cancer Development. Journal of Immunology Research, Artical ID: 318481.
[9] Takanami, I., Imamura, T., Hashizume, T., Kikuchi, K., Yamamoto, Y. and Kodaira, S. (1994) Transforming Growth Factor Beta 1 as a Prognostic Factor in Pulmonary Adenocarcinoma. Journal of Clinical Pathology, 47, 1098-1100.
[10] Hazelbag, S., Kenter, G.G., Gorter, A. and Fleuren, G.J. (2004) Prognostic Relevance of TGF-Beta1 and PAI-1 in Cervical Cancer. International Journal of Cancer, 112, 1020-1028.
[11] Ikeguchi, M., Iwamoto, A., Taniguchi, K., Katano, K. and Hirooka, Y. (2005) The Gene Expression Level of Transforming Growth Factor-Beta (TGF-Beta) as a Biological Prognostic Marker of Hepatocellular Carcinoma. Journal of Experimental & Clinical Cancer Research, 24, 415-421.
[12] Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C.G., Liu, S., Schott, A., Hayes, D., Birnbaum, D., Wicha, M.S. and Dontu, G. (2007) ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell, 1, 555-567.
[13] Minato, T., Yamamoto, Y., Seike, J., Yoshida, T., Yamai, H., Takechi, H., Yuasa, Y., Furukita, Y., Goto, M., Bando, Y. and Tangoku, A. (2013) Aldehyde Dehydrogenase Expression Is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 20, 209-217.
[14] Wu, A., Luo, W., Zhang, Q., Yang, Z., Zhang, G., Li, S. and Yao, K. (2013) Aldehyde Dehydrogenase, a Functional Marker for Identifying Cancer Stem Cells in Human Carcinoma. Cancer Letter, 330, 181-189.